11 – 20 of 57
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
-
Mark
2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases
(
- Contribution to journal › Article
-
Mark
Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?
(
- Contribution to journal › Scientific review
-
Mark
Anti-rheumatic treatment and prosthetic joint infection : An observational study in 494 elective hip and knee arthroplasties
(
- Contribution to journal › Article
-
Mark
Microbiological profile of nosocomial infections following cardiac arrest : Insights from the targeted temperature management (TTM) trial
(
- Contribution to journal › Article
- 2019
-
Mark
Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases : A systematic literature review for the 2019 update of EULAR recommendations
(
- Contribution to journal › Scientific review
-
Mark
Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD) : A systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD
(
- Contribution to journal › Article
- 2017
-
Mark
Cystatin C peptidomimetic derivative with antimicrobial properties as a potential compound against wound infections
(
- Contribution to journal › Article
-
Mark
Outcome of patients with chronic obstructive pulmonary disease and severe coronary artery disease who had a coronary artery bypass graft or a percutaneous coronary intervention
(
- Contribution to journal › Article
- 2016
-
Mark
Childhood hospitalisation with infections and later development of ankylosing spondylitis : A national case-control study
(
- Contribution to journal › Article
- 2014
-
Mark
Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival
(
- Contribution to journal › Scientific review